YSOPIA Bioscience leading biotech in the development of innovative microbiome-based therapies

YSOPIA Bioscience, a leading biotech in next-generation microbiome-based biotherapies that harness the power of keystone single-strain bacteria

more +
lnc
Our Story

Our team is committed to deliver groundbreaking therapeutic solutions to patients with high needs

more +
lnc
therapeutic solutions
lnc

YSOPIA Bioscience is the 1st company to harness the therapeutic potential of Christensenella

Our leadership

Georges RAWADI
Georges RAWADI CEO
Georges RAWADI
CEO

Passionate about innovation

A former researcher at the Institut Pasteur, Georges was Vice-President of Business Development & Intellectual Property and a member of the management team at Celyad.

Sandrine CLAUS
Sandrine CLAUS CSO
Sandrine CLAUS
CSO

Beyond the state of the art

Sandrine joined YSOPIA Bioscience in 2017 as Chief Scientific Officer and is also Associate Professor in Integrative Metabolism in the department of Food and Nutritional Sciences at the University of Reading.

Frédéric Elustondo
Frédéric Elustondo Senior Director of Operations
Frédéric Elustondo
Senior Director of Operations

Execute the right project

Frederic is a trained organic chemist and hold a Ph.D. from the Nottingham University after initial training at the University of Bordeaux.

 
Fabrice GUEZ
Fabrice GUEZ CFO
Fabrice GUEZ
CFO

Putting people first

An experienced CFO, Fabrice decided to switch gears after gaining extensive experience as a financial auditor, getting involved in operations at a number of pharmaceutical SMEs, where he successfully headed up change management processes.

Leveraging partnership for success more +
ICAN
LuinaBio
INRA
Quay Pharma
Cornel University
Bioaster
lnc
Where
to meet us
March 22-25, 2021
BioEurope spring digital
> more
April 28-30, 2021
Pharmabiotic 2021
> more
May 10-15, 2021
China Bio
> more
May 17-19, 2021
Bio€quity Europe digital
> more
June 10-18, 2021
Bio International Convention
> more
Microbiome & us
News
Jul 6, 2021
YSOPIA Successfully Completes Phase 1 Clinical Study of Xla1 Biotherapy for the Treatment of Obesity and Metabolic...
> more
Jun 1, 2021
90 seconds to learn more about YSOPIA Bioscience | [video width="1080" height="1080"...
> more
Press / Media
Jun 16, 2021
Forte de la découverte de Christensenella, une bactérie naturellement présente dans les microbiotes sains, la...
> more
May 24, 2021
Sur un marché mondial estimé à deux milliards de dollars d’ici à 2030, la filière du microbiome pharma veut...
> more
Publications
Jun 21, 2021
In this e-poster presented at the World Microbiome Forum taking place virtually from 20th to 24th June, you will figure...
> more
Jun 9, 2021
by Guillaume Déjean, Héloïse Tudela, Lisa Bruno, Déborah Kissi, Georges Rawadi and Sandrine P. Claus Access to...
> more
now on twitter
YSOPIA Bioscience

Discover how Christensenella bacteria expresses a specific Bile Salt Hydrolase, opening promising avenues to better… t.co/XayltxEqr7

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions Influa | Web Agency © 2018